• Publications
  • Influence
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
BACKGROUND Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonalExpand
  • 143
  • 10
  • PDF
Glucocorticoids induce an activated, anti‐inflammatory monocyte subset in mice that resembles myeloid‐derived suppressor cells
Glucocorticoids (GC) are still the most widely used immunosuppressive agents in clinical medicine. Surprisingly, little is known about the mechanisms of GC action on monocytes, although these cellsExpand
  • 156
  • 10
Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study
Unmet needs exist in actinic keratosis (AK) treatment. Daylight photodynamic therapy (DL‐PDT) has shown good efficacy and safety results compared to conventional PDT (c‐PDT) in a recent Phase IIIExpand
  • 108
  • 9
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician
Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely developExpand
  • 41
  • 3
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients withExpand
  • 22
  • 3
Immune Suppression via Glucocorticoid-Stimulated Monocytes: A Novel Mechanism To Cope with Inflammation
Glucocorticoids (GCs) are used as first-line therapies for generalized suppression of inflammation (e.g., allergies or autoimmune diseases), but their long-term use is limited by severe side effects.Expand
  • 26
  • 2
Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study
Methods The current placebo-controlled multi-center study was designed to assess the effects of the anti-IL-1s monoclonal antibody canakinumab (CAN) on the clinical signs and symptoms of SchS. WeExpand
  • 4
  • 2
Dupilumab treatment improves quality of life in adult patients with moderate‐to‐severe atopic dermatitis: results from a randomized, placebo‐controlled clinical trial
Dupilumab, a human anti‐interleukin‐4 receptor alpha monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate‐to‐severe atopic dermatitis in a randomized,Expand
  • 28
  • 1
Chronic Prurigo of Nodular Type: A Review.
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules. PN evolves along withExpand
  • 34
  • 1
  • PDF
Induction of an anti-inflammatory human monocyte subtype is a unique property of glucocorticoids, but can be modified by IL-6 and IL-10.
Glucocorticoids (GC) are the most widely used immunosuppressive agents in clinical medicine. Recently we showed that GC enhance survival of human monocytes and induce a specific anti-inflammatoryExpand
  • 26
  • 1